Madrigal Pharmaceuticals Inc annual free cash flow for fiscal TTM was -$207 million, a decrease of 8.9% from -$190 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($207M) | ($190M) | ($457M) | ($326M) | ($225M) | ($184M) | ($158M) | ($42M) | ($26M) | ($22M) | ($18M) | ($72M) | ($79M) | ($78M) | ($55M) | ($48M) | ($38M) | ($27M) | ($40M) | $25M | ($55M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $19M | ($171M) | ($134M) | $79M | ($47M) | ($89M) | ($105M) | ($68M) | ($140M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More MDGL metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All MDGL financial statements → Interactive MDGL charts →
About TickerBase · Data methodology & sources · Privacy · Terms